S. Aamdal

S. Aamdal, E. Skovlund, O. Fodstad, 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells.

M. Boyd, S. Aamdal, J. Nesland, 1988, Cancer research.

The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.

S. Aamdal, R. Sciot, B. Geoerger, 2018, European journal of cancer.

Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years' follow-up.

R. Hatlevoll, S. Aamdal, Mari Wang, 2005, Lung cancer.

Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.

S. Aamdal, J. Verweij, C. Sternberg, 1995, European journal of cancer.

Immunomagnetic Detection and Clinical Significance of Micrometastatic Tumor Cells in Malignant Melanoma Patients

S. Aamdal, E. Skovlund, R. Faye, 2004, Clinical Cancer Research.

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

R. Hatlevoll, S. Kaasa, S. Aamdal, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up.

R. Hatlevoll, S. Kaasa, S. Aamdal, 2001, Lung cancer.

hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes

S. Aamdal, G. Kvalheim, G. Gaudernack, 2011, Cancer Immunology, Immunotherapy.

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.

S. Rodenhuis, S. Iacobelli, S. Aamdal, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of the plant protein ricin.

S. Aamdal, O. Fodstad, H. Høst, 1984, Cancer research.

A phase I/II study of Docetaxel (Taxotere) combined with concurrent radiation therapy in locally advanced non-small cell lung cancer (NSCLC)

R. Hatlevoll, S. Aamdal, G. Lauvvang, 2000 .

the critical hurdles in cancer immunotherapy

P. Ascierto, M. Atkins, S. Aamdal, 2012 .

Population‐based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas

F. Langmark, S. Aamdal, L. Akslen, 2008, Genes, chromosomes & cancer.

Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 “CREATE” Trial

D. Lambrechts, S. Aamdal, R. Sciot, 2022, International journal of molecular sciences.

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

S. Aamdal, G. Kvalheim, G. Gaudernack, 2006, Cancer Immunology, Immunotherapy.

EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results

P. Ascierto, S. Aamdal, A. Eggermont, 2008 .

Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods.

S. Aamdal, O. Fodstad, K. Beiske, 1992, The American journal of pathology.

Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis.

S. Aamdal, O. Fodstad, K. Beiske, 1991, The British journal of cancer. Supplement.

Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.

S. Aamdal, S. Leyvraz, M. D’Incalci, 1993, European journal of cancer.

Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity.

S. Aamdal, M. D’Incalci, B. Gerard, 1992, European journal of cancer.

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

J. Wolchok, S. Aamdal, A. Testori, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection

S. Aamdal, G. Kristensen, D. Warren, 2006, BMC clinical pharmacology.

Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment.

S. Aamdal, P. Oian, P. Oian, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

E. Hovig, S. Aamdal, T. Guren, 2022, Journal for ImmunoTherapy of Cancer.

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer

S. Aamdal, Claudius H. Steinfeldt-Reisse, T. Guren, 2020, Frontiers in Immunology.

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine

S. Aamdal, G. Kvalheim, M. Nyakas, 2016, Case reports in medicine.

Sodium thiosulfate fails to increase the therapeutic index of intravenously administered cis-diamminedichloroplatinum (II) in mice bearing murine and human tumors

S. Aamdal, Ø. Fodstad, A. Pihl, 1988, Cancer Chemotherapy and Pharmacology.

Some procedures to reduce cis-platinum toxicity reduce antitumour activity.

S. Aamdal, O. Fodstad, A. Pihl, 1987, Cancer treatment reviews.

The Prognostic Role of Blood Lymphocyte Subset Distribution in Patients With Resected High-risk Primary or Regionally Metastatic Melanoma

S. Aamdal, H. Schmidt, L. Bastholt, 2007, Journal of immunotherapy.

Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels

S. Aamdal, L. Bastholt, J. Lundin, 2015, Cancer Immunology, Immunotherapy.

Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours

S. Aamdal, J. Wanders, J. Vermorken, 2001, Cancer Chemotherapy and Pharmacology.

Human tumor xenografts transplanted under the renal capsule of conventional mice. Growth rates and host immune response

S. Aamdal, Ø. Fodstad, A. Pihl, 1984, International journal of cancer.

A double blind study to evaluate the tolerability of gadodiamide injection and its effect on renal function in patients undergoing cerebral magnetic resonance imaging.

S. Aamdal, K. Berg, B. Lundby, 1993, The British journal of radiology.

9304 Identification of tumor biopsy markers as potential predictors of ipilimumab clinical activity in patients with advanced melanoma

S. Aamdal, S. Chasalow, H. Schmidt, 2009 .

Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy.

S. Fosså, S. Aamdal, B. Naume, 1995, Acta oncologica.

SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance

A. Tsalenko, Z. Yakhini, A. Børresen-Dale, 2010, The Pharmacogenomics Journal.

Correlation of DNA ploidy and S‐phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma

S. Aamdal, S. Wingren, J. Carstensen, 1996, International journal of cancer.

A phase I/II study of telomerase peptide vaccination in combination with chemotherapy in patients with stage IV malignant melanoma.

S. Aamdal, O. Engebraaten, G. Gaudernack, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics of human tumour xenografts transplanted under the renal capsule of immunocompetent mice.

S. Aamdal, J. Nesland, O. Fodstad, 1985, British Journal of Cancer.

Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.

S. Aamdal, R. Paridaens, J. Wanders, 1994, European journal of cancer.

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

S. Aamdal, A. Eggermont, C. Punt, 2009, Journal of the National Cancer Institute.

4LB Results of the Nordic randomised adjuvant trial of intermediate-dose interferon alfa-2b in high-risk melanoma

S. Aamdal, L. Bastholt, J. Hansson, 2007 .

S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients

S. Aamdal, A. Berner, G. Maelandsmo, 2008, Melanoma research.

The preclinical and clinical activity of aviscumine: a potential anticancer drug.

S. Aamdal, H. Zwierzina, L. Bergmann, 2011, European journal of cancer.

Defining the critical hurdles in cancer immunotherapy

Zhigang Tian, Sylvia Janetzki, Cedrik M Britten, 2011, Journal of Translational Medicine.

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’

J. Blay, S. Aamdal, R. Sciot, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.

André Rogatko, Louis M Weiner, R Katherine Alpaugh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neuron specific enolase (NSE) in serum of patients with malignant melanoma.

S. Aamdal, E. Paus, E. Wibe, 1990, Cancer letters.

A new experimental metastasis model in athymic nude mice, the human malignant melanoma lox

J. Nesland, S. Aamdal, Ø. Fodstad, 1988, International journal of cancer.

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.

S. Aamdal, H. McLeod, J. Wanders, 1996, British Journal of Cancer.

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

A. te Velde, S. Aamdal, R. Paridaens, 1996, British Journal of Cancer.

Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study

S. Aamdal, J. Gaullier, S. Dueland, 2009, Acta oncologica.

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

S. Aamdal, G. Kvalheim, E. Helseth, 2013, Cancer Immunology, Immunotherapy.

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

D. Schadendorf, N. Aaronson, M. Muller, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients.

A. Brøgger, S. Aamdal, A. Børresen, 1990, British Journal of Cancer.

T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells

S. Aamdal, G. Kvalheim, G. Gaudernack, 2007, Cancer Immunology, Immunotherapy.

Estrogen receptors and long‐term prognosis in breast cancer

S. Aamdal, O. Kaalhus, G. Eliassen, 1984, Cancer.

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.

S. Aamdal, J. Wanders, A. Eggermont, 2003, European journal of cancer.

Methodological aspects of the 6-day subrenal capsule assay for measuring the response of human tumors to anticancer agents.

S. Aamdal, O. Fodstad, A. Pihl, 1985, Anticancer research.

Chemosensitivity profiles of human cancers assessed by the 6‐day SRC assay on serially xenografted tumors

S. Aamdal, O. Kaalhus, Ø. Fodstad, 1986, International journal of cancer.

Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle.

S. Aamdal, O. Fodstad, O. Kaalhus, 1984, Journal of the National Cancer Institute.

Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas.

M. Boyd, S. Aamdal, O. Fodstad, 1985, Cancer research.

The Usefulness of the Nude Mouse Model for Predicting the Chemosensitivity of Human Tumors. Studies in Malignant Melanoma

S. Aamdal, Ø. Fodstad, A. Pihl, 1988 .

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

S. Aamdal, C. Kersten, G. Gaudernack, 2011, Clinical Cancer Research.

Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin

S. Aamdal, O. Engebraaten, Ø. Fodstad, 2015, British Journal of Cancer.

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Henrik Schmidt, Johan Hansson, Scott D Chasalow, 2011, Journal of Translational Medicine.

Ipilimumab in a real‐world population: A prospective Phase IV trial with long‐term follow‐up

S. Kaasa, H. Russnes, S. Aamdal, 2021, International journal of cancer.

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

E. Hovig, D. Vodák, S. Nakken, 2021, Frontiers in Immunology.

Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients

S. Aamdal, G. Gaudernack, S. Dueland, 2011, Clinical Cancer Research.

S. Aamdal, L. Bastholt, J. Hansson, 2012, European journal of cancer.

Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy

Vessela Kristensen, V. Kristensen, S. Aamdal, 2007, BMC Cancer.

Malignant melanoma--diagnosis, treatment and follow-up in Norway.

Jürgen Geisler, S. Aamdal, L. Akslen, 2013, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Lung colony formation in adult nude mice upon intravenous injection of cells from a human melanoma xenograft. Abstr.

S. Aamdal, K. Tveit, Ø. Fodstad, 1982 .

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

S. Aamdal, K. Taskén, G. Maelandsmo, 2019, Clinical and experimental immunology.

Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma.

S. Aamdal, E. Hannisdal, E. Paus, 1992, European journal of cancer.

Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961.

P. Ascierto, S. Aamdal, A. Eggermont, 2010 .

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

M. Weichenthal, A. Hauschild, H. Pehamberger, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.

S. Aamdal, C. Ingvar, U. Ringborg, 1998, European journal of cancer.

Current approaches to adjuvant therapy of melanoma.

S. Aamdal, 2011, European journal of cancer.

Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy.

S. Aamdal, I. Christensen, A. Eggermont, 2010 .

Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.

J. Blay, S. Aamdal, A. Italiano, 2018 .

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

S. Aamdal, G. Kvalheim, G. Gaudernack, 2005, British Journal of Cancer.

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

S. Aamdal, D. Pietersma, D. Tan, 2012, British Journal of Cancer.

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.

S. Rodenhuis, S. Iacobelli, S. Aamdal, 1989, European Journal of Cancer and Clinical Oncology.

Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma

S. Aamdal, B. Gerard, C. Lucas, 1998, Melanoma research.

Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma

S. Aamdal, L. Bastholt, J. Hansson, 2013, Acta oncologica.

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.

S. Aamdal, R. Kurzrock, I. Smith, 2013, European journal of cancer.

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

P. Ascierto, S. Aamdal, L. Bastholt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study with LTX-315, an immunogenic cell death inducer, in patients with transdermally accessible tumors.

S. Aamdal, Ø. Rekdal, A. Kolstad, 2014 .

Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group.

S. Aamdal, J. Wanders, C. Sessa, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma

S. Aamdal, P. Hersey, M. Millward, 2005, Investigational New Drugs.

Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients.

S. Aamdal, O. Fodstad, K. Flatmark, 2008, Lung cancer.

Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.

P. Fayers, R. Hatlevoll, S. Kaasa, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up

R. Hatlevoll, S. Kaasa, S. Aamdal, 2003 .

Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).

S. Kaasa, S. Aamdal, R. Bremnes, 2005, Lung cancer.

Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.

S. Aamdal, H. McLeod, B. Lund, 1996, European journal of cancer.

328 A phase III study of docetaxel (taxotere) combined with radiation in locally advanced non-small-cell lung cancer (NSCLC)

R. Hatlevoll, S. Aamdal, R. Berg, 1997 .

Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)

S. Aamdal, J. Wanders, J. Verweij, 2000, Cancer Chemotherapy and Pharmacology.

Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.

S. Aamdal, J. Verweij, J. Schellens, 1994, Oncology research.

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours

S. Aamdal, A. Awada, B. Venugopal, 2015, Cancer Chemotherapy and Pharmacology.

Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity

S. Aamdal, J. Wanders, J. Verweij, 1997, Cancer Chemotherapy and Pharmacology.

Cisplatin and etoposide (EP-regimen) is superior to cyclophosphamide, epirubicin, and vincristin (CEV-regimen) in small cell lung cancer: results from a randomized phase III trial with 5 years follow-up

S. Kaasa, S. Aamdal, R. Bremnes, 2001 .

Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy

S. Aamdal, R. Skotheim, S. Saebøe-Larssen, 2021, The Prostate.

Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)

S. Aamdal, J. Wanders, J. Verweij, 2000, Cancer Chemotherapy and Pharmacology.

Transcapillary forces of the subcutaneous tissue in patients treated with interleukin-2 and alpha-interferon: no capillary protein leak syndrome?

S. Fosså, S. Aamdal, P. Oian, 1996, Journal of experimental therapeutics & oncology.

Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma

S. Aamdal, F. Garrido, G. González-Aseguinolaza, 2014, International journal of cancer.

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

S. Aamdal, C. Kersten, G. Gaudernack, 2011, Clinical Cancer Research.

Sequential administration of dacarbazine and fotemustine in disseminated melanoma

S Aamdal, SM Lee, JA Radford, 1991 .

P. Fayers, R. Hatlevoll, S. Kaasa, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I study of men-10755 in patients with a solid tumor as a shorti.v. infusion given once every 3 weeks

S. Aamdal, S. Peters, J. Wanders, 1999 .

Taxotere in advanced malignant melanoma: A fase-II trial of the eortc early clinical trials group

M. Piccart, S. Aamdal, R. Paridaens, 1993 .

Acute liver graft rejection after ipilimumab therapy.

K. Boberg, S. Aamdal, T. Guren, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

P. Ascierto, S. Aamdal, L. Bastholt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes

S. Aamdal, G. Kvalheim, G. Gaudernack, 2011, Cancer Immunology, Immunotherapy.